CN106727591A - A kind of pharmaceutical composition for treating Streptococcus suis - Google Patents
A kind of pharmaceutical composition for treating Streptococcus suis Download PDFInfo
- Publication number
- CN106727591A CN106727591A CN201611239755.2A CN201611239755A CN106727591A CN 106727591 A CN106727591 A CN 106727591A CN 201611239755 A CN201611239755 A CN 201611239755A CN 106727591 A CN106727591 A CN 106727591A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- streptococcus suis
- treatment
- talastisamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating Streptococcus suis, the pharmaceutical composition of the treatment Streptococcus suis is according to the primary raw material of weight portion：5 16 parts of methenamine, 26 parts of toosendanin, 9 10 parts of evodin, 25 32 parts of Gomisin G, 15 23 parts of colchicin, 24 parts of 11- ketone groups masticinic acid, 6 10 parts of ephedrine, 0.5 1.4 parts of epoxylathyrol, different 89 parts of capsule of weeping forsythia fat glycosides, 24 parts of talastisamine.Medicine of the present invention is strictly selected material composition according to the understanding mechanism of Streptococcus suis, so as to reach the purpose of comprehensive rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of pharmaceutical composition for treating Streptococcus suis.
Background technology
Streptococcus suis are called pig blood dysentery, are a kind of serious enteric infections caused by Streptococcus suis treponema
Disease, main clinical symptom is serious mucus hemorrhagic diarrhea, acute based on hemorrhagic diarrhea, it is subacute and it is chronic with
Based on mucous diarrhoea is scheduled to last.Cut open inspection pathological characters are that colorectal mucosa occurs Catarrhal, hemorrhagic and gangrenous inflammation.In nature
In the case of, only pig morbidity, various ages, the pig of kind can all infect, but mainly what is encroached on is the piglet at 2-3 monthly ages；Piggy
Morbidity and mortality it is all higher than big pig；Sick pig and carrier are main source of infection, and the generation of this disease is without obvious season
Property；Due to the presence of the pig that carries disease germs, transferred frequently by swinery and dealing pig scatters disease.Carried disease germs pig, and pipe is raised normal
Often do not fallen ill under the conditions of reason, when the unfavorable factor, raising deficiency for having reduction pig body resistance, be deficient in vitamin and stress factor
When, just can promote to cause morbidity.Sick pig is treated in time, drug therapy, often there is a certain effect, such as LIJUNJING (MAQO, 3- methyl-
Acetyl group-quinoline dislikes woods-Isosorbide-5-Nitrae-dioxide) 5mg/kg, take orally, 2 times a day, and it is a course for the treatment of to take medicine continuously 3, or by 0.5% dysentery bacterium
Net solution 0.5ml/kg, intramuscular injection；The pyridine of diformazan nitro miaow, neomycinsulphate, furazolidone, lincomycin, telracycline family antibiosis
Various antibacterials such as element have certain curative effect.Although this drug therapy has certain effect, but the problem brought is anti-
Raw element residual quantity is high.Antibiotic may enter human body with pork, easily produce antibiotic resistance to human body.Therefore we
Need to find a kind of this kind of disease of new drug therapy.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition for treating Streptococcus suis, to solve above-mentioned background technology
The problem of middle proposition.
To achieve the above object, the present invention provides following technical scheme：
A kind of pharmaceutical composition for treating Streptococcus suis, be according to the primary raw material of weight portion：Methenamine 5-16 parts,
Toosendanin 2-6 parts, evodin 9-10 parts, Gomisin G 25-32 parts, colchicin 15-23 parts, 11- ketone group masticinic acids 2-
4 parts, ephedrine 6-10 parts, epoxylathyrol 0.5-1.4 parts, 8-9 parts, talastisamine 2-4 parts of different capsule of weeping forsythia fat glycosides.
As further scheme of the invention：The pharmaceutical composition of the treatment Streptococcus suis, according to the master of weight portion
The raw material is wanted to be：Methenamine 8-12 parts, toosendanin 3-5 parts, evodin 9-10 parts, Gomisin G 28-30 parts, colchicin
18-21 parts, 2-4 parts of 11- ketone group masticinic acids, ephedrine 6-10 parts, epoxylathyrol 0.5-1.4 parts, different capsule of weeping forsythia fat glycosides 8-9
Part, talastisamine 2-4 parts.
As further scheme of the invention：The pharmaceutical composition of the treatment Streptococcus suis, according to the master of weight portion
The raw material is wanted to be：10 parts of methenamine, 4 parts of toosendanin, 10 parts of evodin, 29 parts of Gomisin G, 19 parts of colchicin, 11-
3 parts of ketone group masticinic acid, 8 parts of ephedrine, 0.9 part of epoxylathyrol, different 9 parts of capsule of weeping forsythia fat glycosides, 3 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating Streptococcus suis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, methenamine, toosendanin, evodin, dagger-axe rice are weighed by above-mentioned metering ratio
Pungent G, colchicin, 11- ketone groups masticinic acid, ephedrine, epoxylathyrol, different capsule of weeping forsythia fat glycosides, talastisamine, sieving, machine
Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature after mixing
Dry, at 4-8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of Streptococcus suis to temperature control.
As further scheme of the invention：Mix 6min in specific steps.
Compared with prior art, the beneficial effects of the invention are as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of Streptococcus suis, so as to reach comprehensively
The purpose of rehabilitation, with rapid-action, effect stabilization, carry convenient to take, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of pharmaceutical composition for treating Streptococcus suis, be according to the primary raw material of weight portion：5 parts of methenamine, river
2 parts of chinaberry element, 9 parts of evodin, 25 parts of Gomisin G, 15 parts of colchicin, 2 parts of 11- ketone groups masticinic acid, 6 parts of ephedrine,
0.5 part of epoxylathyrol, different 8 parts of capsule of weeping forsythia fat glycosides, 2 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating Streptococcus suis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, methenamine, toosendanin, evodin, dagger-axe rice are weighed by above-mentioned metering ratio
Pungent G, colchicin, 11- ketone groups masticinic acid, ephedrine, epoxylathyrol, different capsule of weeping forsythia fat glycosides, talastisamine, sieving, machine
Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 4 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of Streptococcus suis to temperature control.
Embodiment 2
A kind of pharmaceutical composition for treating Streptococcus suis, be according to the primary raw material of weight portion：8 parts of methenamine, river
3 parts of chinaberry element, 9 parts of evodin, 28 parts of Gomisin G, 18 parts of colchicin, 2 parts of 11- ketone groups masticinic acid, 6 parts of ephedrine,
0.5 part of epoxylathyrol, different 8 parts of capsule of weeping forsythia fat glycosides, 2 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating Streptococcus suis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, methenamine, toosendanin, evodin, dagger-axe rice are weighed by above-mentioned metering ratio
Pungent G, colchicin, 11- ketone groups masticinic acid, ephedrine, epoxylathyrol, different capsule of weeping forsythia fat glycosides, talastisamine, sieving, machine
Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 4min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 4 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of Streptococcus suis to temperature control.
Embodiment 3
A kind of pharmaceutical composition for treating Streptococcus suis, be according to the primary raw material of weight portion：10 parts of methenamine, river
4 parts of chinaberry element, 10 parts of evodin, 29 parts of Gomisin G, 19 parts of colchicin, 3 parts of 11- ketone groups masticinic acid, 8 parts of ephedrine,
0.9 part of epoxylathyrol, different 9 parts of capsule of weeping forsythia fat glycosides, 3 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating Streptococcus suis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, methenamine, toosendanin, evodin, dagger-axe rice are weighed by above-mentioned metering ratio
Pungent G, colchicin, 11- ketone groups masticinic acid, ephedrine, epoxylathyrol, different capsule of weeping forsythia fat glycosides, talastisamine, sieving, machine
Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 6min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 6 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of Streptococcus suis to temperature control.
Embodiment 4
A kind of pharmaceutical composition for treating Streptococcus suis, be according to the primary raw material of weight portion：12 parts of methenamine, river
5 parts of chinaberry element, 10 parts of evodin, 30 parts of Gomisin G, 21 parts of colchicin, 4 parts of 11- ketone groups masticinic acid, ephedrine 10
Part, 1.4 parts of epoxylathyrol, different 9 parts of capsule of weeping forsythia fat glycosides, 4 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating Streptococcus suis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, methenamine, toosendanin, evodin, dagger-axe rice are weighed by above-mentioned metering ratio
Pungent G, colchicin, 11- ketone groups masticinic acid, ephedrine, epoxylathyrol, different capsule of weeping forsythia fat glycosides, talastisamine, sieving, machine
Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of Streptococcus suis to temperature control.
Embodiment 5
A kind of pharmaceutical composition for treating Streptococcus suis, be according to the primary raw material of weight portion：16 parts of methenamine, river
6 parts of chinaberry element, 10 parts of evodin, 32 parts of Gomisin G, 23 parts of colchicin, 4 parts of 11- ketone groups masticinic acid, ephedrine 10
Part, 1.4 parts of epoxylathyrol, different 9 parts of capsule of weeping forsythia fat glycosides, 4 parts of talastisamine.
A kind of preparation method of the pharmaceutical composition for treating Streptococcus suis, concretely comprises the following steps：
First, in pharmaceutical grade clean area, methenamine, toosendanin, evodin, dagger-axe rice are weighed by above-mentioned metering ratio
Pungent G, colchicin, 11- ketone groups masticinic acid, ephedrine, epoxylathyrol, different capsule of weeping forsythia fat glycosides, talastisamine, sieving, machine
Tool adds ultra-pure water after mixing, place in pharmacy mixer, mixes 8min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of Streptococcus suis to temperature control.
Pharmacology test
1st, chronic toxicity test
It is experiment with pharmaceutical composition obtained in the embodiment of the present invention 3, using gastric infusion mode, is continuously given in 24h
Medicine 2 times, per minor tick 8h, is administered 300mg/kg doses every time, and daily accumulation medicine total amount reaches 600mg medicines/kg, equivalent to pig
100 times of quantity.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, hair color light, and its is average
Body weight increases with the extension of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney,
Brain, thymus gland, stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).Result shows：This hair
Bright pharmaceutical composition is without chronic toxicity.
2nd, long term toxicity test
It is experiment with pharmaceutical composition obtained in the embodiment of the present invention 3, using gastric infusion mode, by medicine group of the present invention
Compound is divided into low dosage, middle dosage, three groups of high dose, the drug dose of each group is respectively 60,120,180mg medicines/kg/d, phase
When in 10,20,30 times of clinical dosage.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematology
Mark, blood parameters without obvious influence, Systematic anatomy, organ coefficient and histopathological examination also no abnormal disease
Reason changes.It is discontinued 2 weeks and also has no substantially change.Result shows：Pharmaceutical composition of the present invention does not find in long term toxicity test
Overt toxicity reacts and delayed toxicity reaction.It can be seen that, pharmaceutical composition non-toxic reaction of the present invention, long-term prescription is safe and reliable.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires to be limited rather than described above, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each implementation method is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity, those skilled in the art should
Specification an as entirety, the technical scheme in each embodiment can also be formed into those skilled in the art through appropriately combined
May be appreciated other embodiment.
Claims (5)
1. a kind of pharmaceutical composition for treating Streptococcus suis, it is characterised in that the primary raw material according to weight portion is：Wu Luotuo
Product 5-16 parts, toosendanin 2-6 parts, evodin 9-10 parts, Gomisin G 25-32 parts, colchicin 15-23 parts, 11- ketone
2-4 parts of base masticinic acid, ephedrine 6-10 parts, epoxylathyrol 0.5-1.4 parts, 8-9 parts of different capsule of weeping forsythia fat glycosides, talastisamine 2-
4 parts.
2. it is according to claim 1 treatment Streptococcus suis pharmaceutical composition, it is characterised in that the treatment pig hammer
The pharmaceutical composition of bacterium disease, be according to the primary raw material of weight portion：Methenamine 8-12 parts, toosendanin 3-5 parts, evodin
9-10 parts, Gomisin G 28-30 parts, colchicin 18-21 parts, 2-4 parts of 11- ketone group masticinic acids, ephedrine 6-10 parts, epoxy
Lathyrol 0.5-1.4 parts, 8-9 parts, talastisamine 2-4 parts of different capsule of weeping forsythia fat glycosides.
3. it is according to claim 1 and 2 treatment Streptococcus suis pharmaceutical composition, it is characterised in that the treatment pig
The pharmaceutical composition of streptococcosis, be according to the primary raw material of weight portion：10 parts of methenamine, 4 parts of toosendanin, evodin
10 parts, 29 parts of Gomisin G, 19 parts of colchicin, 3 parts of 11- ketone groups masticinic acid, 8 parts of ephedrine, 0.9 part of epoxylathyrol,
Different 9 parts of capsule of weeping forsythia fat glycosides, 3 parts of talastisamine.
4. it is a kind of as described in claim 1-3 is any treatment Streptococcus suis pharmaceutical composition preparation method, its feature
It is to concretely comprise the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh methenamine, toosendanin, evodin, Gomisin G,
Colchicin, 11- ketone groups masticinic acid, ephedrine, epoxylathyrol, different capsule of weeping forsythia fat glycosides, talastisamine, sieving, machinery are mixed
Addition ultra-pure water after even, places in pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing,
At 4-8 DEG C, packaging obtains final product the pharmaceutical composition for the treatment of Streptococcus suis to temperature control.
5. the preparation method of the pharmaceutical composition for the treatment of Streptococcus suis according to claim 4, it is characterised in that specific
Mix 6min in step.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611239755.2A CN106727591A (en) | 2016-12-28 | 2016-12-28 | A kind of pharmaceutical composition for treating Streptococcus suis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611239755.2A CN106727591A (en) | 2016-12-28 | 2016-12-28 | A kind of pharmaceutical composition for treating Streptococcus suis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727591A true CN106727591A (en) | 2017-05-31 |
Family
ID=58923168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611239755.2A Pending CN106727591A (en) | 2016-12-28 | 2016-12-28 | A kind of pharmaceutical composition for treating Streptococcus suis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727591A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789614A (en) * | 2017-11-27 | 2018-03-13 | 河北新世纪药业有限公司 | A kind of pharmaceutical composition for preventing and treating sea cucumber disease and preparation method thereof |
-
2016
- 2016-12-28 CN CN201611239755.2A patent/CN106727591A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789614A (en) * | 2017-11-27 | 2018-03-13 | 河北新世纪药业有限公司 | A kind of pharmaceutical composition for preventing and treating sea cucumber disease and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101905014B (en) | Traditional Chinese medicine compound composition for treating diarrhea of weaned piglets | |
| Zhou et al. | Preventive effect of insect tea against reserpine‑induced gastric ulcers in mice | |
| CN114502141A (en) | Plant extract mixture for preventing and/or treating chronic inflammatory bowel disease | |
| CN106727591A (en) | A kind of pharmaceutical composition for treating Streptococcus suis | |
| CN106619666A (en) | Pharmaceutical composition for treating swine dysentery | |
| ES2822660T3 (en) | Preparation for the treatment of arthritis and osteoarthritis | |
| CN106580948A (en) | Pharmaceutical composition for treating swine dysentery | |
| CN102670899B (en) | Compound propolis composition for treating cattle and sheep fascioliasis and preparation method thereof | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN106619874A (en) | Drug composition used for treating swine dysentery | |
| CN102973755A (en) | Composition for treating ascariasis and teniasis in livestock and poultry, and preparation method thereof | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN102319318A (en) | Chinese medicinal superfine powder preparation for preventing and treating heat toxin and blood dysentery of chicken and preparation method thereof | |
| CN106822133A (en) | A kind of Western medicine compound for treating acute diarrhea | |
| CN105079412A (en) | Veterinary compound traditional Chinese medicine injection and preparation method thereof | |
| CN106727508A (en) | A kind of combination drug for treating chronic dysentery | |
| CN106822239A (en) | It is a kind of to treat Chinese and western medicinal composition of the infection of the upper respiratory tract and preparation method thereof | |
| CN105876110A (en) | Traditional Chinese medicine additive for meat chicken breeding | |
| CN106619890A (en) | Chinese and Western medicine composition for treating ascariasis and preparation method thereof | |
| CN106727786A (en) | A kind of antipyretic of children's Integrated TCM and preparation method thereof | |
| CN104069180B (en) | The preparation method of compound bark of ash poplar flower effervescent granules | |
| KR20240070850A (en) | Pharmaceutical composition for treating constipation | |
| CN106619682A (en) | Pharmaceutical composition for treating porcine diarrhea | |
| CN106619650A (en) | Compound preparation for treating chronic glomerulitis | |
| CN104069236B (en) | Compound bark of ash poplar flower effervescent granules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170531 |